Navigation Links
Tools for more accurate dosage of drugs against HIV/AIDS and malaria
Date:3/6/2009

A doctoral thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden, shows that it is possible to describe and quantify the relationships between dose, concentration and effectiveness of several drugs against HIV/AIDS and malaria. The method may allow improved treatment and fewer undesired effects for patients with these diseases.

Registered pharmacist Daniel Rshammar has in his thesis studied the optimal use of certain pharmaceutical substances that are used to combat HIV/AIDS and malaria. He has analysed, among other things, data from 121 healthy volunteers from Uganda using a mathematical model known as a pharmacometric model. The study showed that both sex and genetic differences between individuals influence the way in which the body metabolises efavirenz, which is part of some anti-HIV/AIDS drugs. Other studies have focussed on 74 people from Zimbabwe with HIV/AIDS, and showed that a reduction in the daily dose of efavirenz from 600 mg to 400 mg can reduce the risk of undesired effects in those affected who have a genetically conditioned poorer ability to catabolise the substance.

"Many HIV/AIDS patients are treated with efavirenz, and they should be genetically tested using a blood test before deciding on a dose. This is particularly important in Africa, where the fraction of patients with a poorer catabolic ability is greater than it is elsewhere", says Daniel Rshammar.

Repeated measurements of the drug concentrations and virus levels in 239 previously untreated Scandinavian patients with HIV/AIDS allowed a similar model to be used in order to study the antiretroviral effects of anti-HIV/AIDS drugs. Calculations showed that treatment in which efavirenz was combined with other pharmaceutical substances was more effective than two other frequently used combination treatments.

"It may be possible in the future to use the model to predict when the treatment will loose its effectiveness for an individual patient, and explain why", says Daniel Rshammar.

Further work involved using a model to describe how the catabolism of the anti-malarial drug artemisinin increases and the concentration of the drug decreases when patients take this drug. When artemisinin was given to 97 patients in Vietnam without other drugs, approximately 37% of them were affected by recrudescent malaria. The model showed that this could not be explained solely by low drug concentrations. Another anti-malarial drug, piperaquine, may be a suitable partner for artemisinin in the treatment of malaria. An investigation of 12 Vietnamese study subjects, however, allowed scientists to estimate that the levels of piperaquine that remain in the body are too low to be effective, and this increases the risk that the malaria parasite will develop resistance.

"Research shows that pharmacometric models can be adapted to patient data in order to understand the relationships between drug concentration, effectiveness and the progress of disease, while at the same time taking into consideration differences between patients such as, for example, weight, age, sex, genetic factors, other diseases and other drugs. We expect that these tools will be important in the fight against HIV/AIDS and malaria", says Daniel Rshammar.


'/>"/>

Contact: Ulrika Lundin
ulrika.lundin@sahlgrenska.gu.se
46-707-758-851
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. Mannatech Launches Phase One of New Sales and Training Tools
2. Academy releases emergency preparedness tools to enable millions more people to shelter in place
3. New AHRQ Tools Help Pharmacies Better Serve Patients With Limited Health Literacy
4. U.S. Army Selects Cogon Systems to Develop Advanced Clinical Decision Support Tools for Hand Held Computers
5. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
6. AUDIO from Medialink and P&G: New Tools for Promoting Good Mouth Health
7. Design of patient tracking tools may have unintended consequences
8. New research tools are too complex for easy answers, researchers say
9. HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools
10. Health and Technology Leaders Tackle Challenge of Managing Consumers Identities in Web-Based Personal Health Tools
11. Mayo Clinic, Microsoft Announce Strategic Agreement to Develop Consumer Health Management Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Medic CE , a Career Step company, is ... Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to ... presented by Captain Rommie Duckworth, LP, a career fire captain as well as founder ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after actor, and ... “Informed” brings the public important topics from all aspects of life, and a new ... issues surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... based sleep diagnostics sensors, announced today it had completed the first phase of ... mix of domestic and rest of world (ROW) authorized dealers specializing in polysomnography ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... ... The National Council on Strength and Fitness (NCSF), a ... Strength Coach credential has earned accreditation from the National Commission for Certifying Agencies ... qualified candidates for jobs in the Strength and Conditioning profession. The CSC distinction ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
Breaking Medicine Technology: